Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot O75445: Variant p.Arg334Trp

Usherin
Gene: USH2A
Feedback?
Variant information Variant position: help 334 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Arginine (R) to Tryptophan (W) at position 334 (R334W, p.Arg334Trp). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to large size and aromatic (W) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In USH2A. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 334 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 5202 The length of the canonical sequence.
Location on the sequence: help LAQRYCIPNDAGDTADNRVS R LNPEAHPLSFVNDNDVGTSW The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         LAQRYCIPNDAGDTADNRVSRLNPEAHPLSFVNDNDVGTSW

Mouse                         SVQQYCIPNGAGDTPEHRMSRLNPEAHPLSFINDDDVATSW

Rat                           SVQQYCIPNGVEDTLQHRVSRLNPEAHPLSFINDDDVATSW

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 32 – 5202 Usherin
Topological domain 32 – 5042 Extracellular
Domain 271 – 517 Laminin N-terminal



Literature citations
Three novel mutations and twelve polymorphisms identified in the USH2A gene in Israeli USH2 families.
Adato A.; Weston M.D.; Berry A.; Kimberling W.J.; Bonne-Tamir A.;
Hum. Mutat. 15:388-388(2000)
Cited for: VARIANTS USH2A TRP-334 AND MET-1515; VARIANTS ASP-478; VAL-644 AND LYS-1486; Mutational spectrum in Usher syndrome type II.
Ouyang X.M.; Yan D.; Hejtmancik J.F.; Jacobson S.G.; Li A.R.; Du L.L.; Angeli S.; Kaiser M.; Balkany T.; Liu X.Z.;
Clin. Genet. 65:288-293(2004)
Cited for: VARIANTS USH2A TRP-334; HIS-346 AND THR-357; VARIANTS SER-479 AND VAL-644; Molecular and in silico analyses of the full-length isoform of usherin identify new pathogenic alleles in Usher type II patients.
Baux D.; Larrieu L.; Blanchet C.; Hamel C.; Ben Salah S.; Vielle A.; Gilbert-Dussardier B.; Holder M.; Calvas P.; Philip N.; Edery P.; Bonneau D.; Claustres M.; Malcolm S.; Roux A.-F.;
Hum. Mutat. 28:781-789(2007)
Cited for: VARIANTS USH2A GLU-218; PHE-280; LYS-284; TRP-334; GLN-334; HIS-346; ILE-352; PHE-759; GLU-1833; SER-2795; ARG-3282; MET-3571; GLU-3895; MET-3976; CYS-4115 AND MET-4425; VARIANT PHE-1572; Four USH2A founder mutations underlie the majority of Usher syndrome type 2 cases among non-Ashkenazi Jews.
Auslender N.; Bandah D.; Rizel L.; Behar D.M.; Shohat M.; Banin E.; Allon-Shalev S.; Sharony R.; Sharon D.; Ben-Yosef T.;
Genet. Test. 12:289-294(2008)
Cited for: VARIANTS USH2A TRP-334 AND VAL-1840; Spectrum of USH2A mutations in Scandinavian patients with Usher syndrome type II.
Dreyer B.; Brox V.; Tranebjaerg L.; Rosenberg T.; Sadeghi A.M.; Moeller C.; Nilssen O.;
Hum. Mutat. 29:451-451(2008)
Cited for: VARIANTS USH2A TYR-163; ARG-268; CYS-303; TRP-334; HIS-346; ILE-352; ARG-536; PHE-759; LEU-1212; 2265-GLU-TYR-2266 DELINS ASP; GLY-3124; THR-3504; ARG-3521; ILE-4054; ARG-4232; ILE-4439; CYS-4487; HIS-4592 AND ARG-4795; VARIANTS THR-125; MET-230; ASP-478; SER-595; VAL-644; ARG-713; PRO-1349; LYS-1486; PHE-1572; THR-1665; CYS-1757; ASN-2080; ASN-2086; THR-2106; THR-2169; ALA-2238; HIS-2292; ALA-2562; GLN-2875; PHE-2886; LYS-3088; SER-3099; ALA-3115; ASN-3144; ASP-3199; ALA-3411; LEU-3590; ILE-3835; VAL-3868; THR-3893; CYS-4115; LEU-4433; VAL-4624 AND TRP-5031; Microarray-based mutation analysis of 183 Spanish families with Usher syndrome.
Jaijo T.; Aller E.; Garcia-Garcia G.; Aparisi M.J.; Bernal S.; Avila-Fernandez A.; Barragan I.; Baiget M.; Ayuso C.; Antinolo G.; Diaz-Llopis M.; Kulm M.; Beneyto M.; Najera C.; Millan J.M.;
Invest. Ophthalmol. Vis. Sci. 51:1311-1317(2010)
Cited for: VARIANTS USH2A TRP-334 AND VAL-555;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.